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Abstract
Background—Polypills which include multiple medications for reducing cardiovascular disease
(CVD) risk in a single pill have been proposed for population-wide use. The number of US adults
eligible for polypills and potential benefits are unknown.
Methods—The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008
were analyzed to estimate treatment rates for medications proposed for inclusion in polypills
(aspirin, statin, an ACE-inhibitor, and a thiazide-type diuretic for those without, a beta-blocker for
those with, a history of myocardial infarction) among US adults. The number of coronary heart
disease (CHD) and stroke events potentially prevented through polypill use was projected by
published meta-analyses and three large population-based cohort studies. Two polypill eligibility
criteria were analyzed (1) US adults ≥ 55 years and (2) US adults with a history of CVD.
Results—There are 67.6 million US adults ≥ 55 years and 15.4 million US adults with a history
of CVD and, thus, eligible for polypills using the two outlined criteria. In 2007-2008, 37.3% of US
adults ≥ 55 years and 57.0% of those with a history of CVD were taking statins. Use of other
polypill medications was also low. Polypill use by US adults age ≥ 55 years is projected to
potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Amongst those
with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes
is projected.
Conclusions—Polypills have the potential to lower CVD incidence substantially among US
adults.
In 2001, participants in a meeting of the World Health Organization and Wellcome Trust
discussed the development of fixed dose combination medications for the secondary
prevention of cardiovascular disease (CVD)(1). In 2003, Wald and Law proposed a
“Polypill” which would include multiple pharmacological therapies aimed at reducing CVD
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risk by attacking several biological processes simultaneously(2). Rather than limiting the
polypill to secondary prevention, it has been proposed as a public health intervention for use
by all adults ≥ 55 years of age regardless of, and with little to no monitoring of, risk factor
levels. Using such a population-based approach, polypills have been projected to result in
reductions in coronary heart disease (CHD) and stroke incidence as high as 88% and 80%,
respectively(2). Multiple different polypill formulations have been developed over the past 5
years, with randomized controlled trials of their benefit currently underway(3-5).
The purpose of the current analysis was to determine the number of US adults eligible for
polypills aimed at reducing CVD risk. As the criteria for polypill eligibility are not fixed, we
investigated the number of eligible US adults using two approaches: (1) a population-based
approach as recommended by Wald and Law in which all US adults age ≥ 55 years would
be recommended polypills, and (2) a high risk approach wherein those with a history of
CVD would be recommended a polypill. Additionally, we calculated the proportion of each
of these populations currently taking cardio-protective medications including aspirin,
antihypertensive medications, and statins and projected the number of CHD and stroke
events that could be prevented through the administration of polypills in these populations.
Methods
Study Population
The National Health and Nutrition Examination Survey (NHANES) is conducted in two
year cycles with each cycle including representative samples of the non-institutionalized
civilian population of the US(6). The main analyses included 2,554 participants, 20 years
and older, who completed an in-home interview and a medical evaluation as part of
NHANES 2007-2008. Analyses including LDL-cholesterol and fasting plasma glucose
values were based on 977 participants whose medical evaluation was conducted after an
overnight fast of 9 or more hours. While NHANES 2007-2008 included a pill bottle review
to capture prescription medication use, daily aspirin use was not collected in this survey
cycle. Thus, daily aspirin use was obtained from NHANES 2003-2004 (n=2,112).
Data Collection
Questionnaires were used to record demographics, cigarette smoking, personal and family
history of CHD, and history of diabetes. Diabetes was defined as a self-report of a previous
diagnosis while not pregnant and/or current antidiabetes medication use and/or fasting
plasma glucose ≥ 126 mg/dL. Blood pressure was measured three times and averaged(7).
Hypertension was defined as a systolic blood pressure ≥ 140 mmHg and/or diastolic blood
pressure ≥ 90 mmHg and/or current antihypertensive medication use. Current use of
antihypertensive medication classes and statins was determined through pill bottle review by
trained study staff. Aspirin use was ascertained via standardized questions and flash cards
listing different types of analgesic medications. Participants with LDL-cholesterol exceeding
cut-points defined in the National Cholesterol Education Panel Adult Treatment Panel III
guidelines (≥ 160 mg/dL for adults without CHD and 0-1 CHD risk factors, ≥ 130 mg/dL
for adults without CHD and ≥ 2 CHD risk factors, and ≥ 70 mg/dL for adults with CHD or a
CHD risk equivalent) or taking statins were considered to have high LDL-cholesterol(8).
Eligible populations—Two populations were evaluated for potential polypill use. The
first population, included all US adults ≥ 55 years of age. The second population included
individuals with a history of CVD defined as a self-report of a prior diagnosis of myocardial
infarction, CHD, or stroke by a healthcare professional.
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Treatment recommendations—Current treatment recommendations for aspirin,
antihypertensive medications and statins were based on published guidelines. Aspirin
therapy is recommended for adults with a history of CVD or a 10-year risk of CHD ≥
10%(9). Antihypertensive medications and statins are recommended for adults with
hypertension and high LDL-cholesterol, respectively. Beta-blockers are recommended for
adults with a history of myocardial infarction(10).
Polypill ingredients—Two polypill formulations which are currently being evaluated in
randomized controlled trials were investigated for the current analysis(11). Polypill one was
assumed to contain aspirin, an ACE-inhibitor, a thiazide-type diuretic, and a statin, and was
deemed applicable for the general population without a history of myocardial infarction.
Polypill two was assumed to contain aspirin, an ACE-inhibitor, a beta-blocker, and a statin,
and was deemed applicable for those with a history of myocardial infarction.
Projected CVD risk reduction with polypill use—The expected reduction in CHD
and stroke incidence due to medication use was obtained from published meta-analyses. For
aspirin, the risk reduction benefits (95% CI) for individuals without and with a history of
CVD were 18% (10%, 25%) and 20% (12%, 27%), respectively, for CHD and 5% (-17%,
+10%) and 19% (4%, 32%), respectively, for stroke. The CHD and stroke risk reduction
benefits were 26% (23%, 29%) and 16% (95% CI: 9%, 21%) for statins, 20% (12%, 27%)
and 28% (19%, 36%) for ACE-inhibitors, 21% (8%, 31%) and 29% (19%, 37%) for low-
dose diuretics, and 7% (0%, 19%) and 20% (4%, 34%) for beta-blockers(12-18). As such,
assuming independent multiplicative effects, in a population not receiving treatment,
polypill one (aspirin, ACE-inhibitor, thiazide-type diuretic, and at statin for primary
prevention) is projected to reduce the incidence of CHD and stroke by 62% and 59%,
respectively, and polypill two (aspirin, ACE-inhibitor, beta-blocker, and a statin for
secondary prevention) is projected to reduce the incidence of CHD and stroke by 61% and
59%, respectively.
Projected side effects with polypill use—The rates (95% CI) of side effects from
aspirin, thiazide-type diuretics, ACE-inhibitors, beta-blockers and statins have been reported
to be 3.9% (2.2%, 5.6%), 9.9% (6.6%, 13.2%), 3.9% (-0.5%, 8.3%), 7.5% (4.0%, 10.9%),
and 0.1% (-1%, 1%), respectively(2;19;20). Assuming independent additive effects,
polypills one and two are estimated to result in side-effects in 17.8% and 15.4% of its users,
respectively.
Individuals already taking components of the polypills (e.g., statins) were projected to
experience only the risk reduction benefit and side effect disadvantage from the polypill
ingredients that they were not already taking.
Incidence rates of coronary heart disease—CHD and stroke incidence rates for all
adults ≥ 55 years of age and individuals with a history of CVD, separately, were determined
by pooling individual-level data from limited-access databases for three prospective
population-based cohort studies: the Framingham Offspring Study, the Atherosclerosis Risk
in Communities Study (ARIC), and the Cardiovascular Health Study (CHS)(21-23). In the
pooled data set used for analysis, there were 14,568 adults ≥ 55 years of age and 3,104
adults with a history of CVD. Event data in the public-access datasets are limited to 9 years
of follow-up. Ten-year event rates were calculated by multiplying the 9 year event rates by
10 and dividing this product by 9. Protocols were approved by the relevant institutional
review boards and informed consent was obtained from all study participants.
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Two parallel analyses were performed, one for each set of polypill eligibility criteria (i.e.,
[1] the general population approach of US adults ≥ 55 years of age and [2] restricted to
individuals with a history of CVD). Using NHANES 2007-2008, the number and
characteristics of US adults eligible for polypills was calculated. The percentages of
polypill-eligible US adults recommended aspirin, antihypertensive medications and statins
under current treatment guidelines were calculated. Additionally, the percentage of those
recommended each therapy who was actually taking it was calculated.
The 10-year incidence rates of CHD and stroke was calculated for adults ≥ 55 years of age
and individuals with a history of CVD using data from the pooled Framingham Offspring
Study, ARIC Study, and CHS cohort databases. The number of CHD and stroke events
expected to occur over the next 10 years among US adults was calculated as the product of
these incidence rates and the number of US adults ≥ 55 years and the number of US adults
with a history of CVD, according to NHANES 2007-2008. The percent and number of CHD
and stroke events potentially saved, over 10 years, simulating polypill use, was projected by
applying the risk reduction rates from meta-analyses to the expected number of CHD and
stroke events among the population eligible for polypill use. An identical approach was
taken to estimate the number of side effects caused by polypill use. Sensitivity analyses were
conducted by calculating the risk reduction and side effects projections of the two polypills
using the lower (worst case) and upper bounds (best case) of the confidence intervals from
the meta-analyses. Also, as individuals not currently taking antihypertensive medications or
statins may not take a polypill, a separate sensitivity analysis was conducted to assess the
reduction in CHD and stroke incidence and side effects, assuming that only individuals
already taking at least one of these medications would take a polypill. Finally, as the benefit
of polypill medications may not be multiplicative when combined, we also projected the
benefits of polypills using a sub-multiplicative model wherein each medication was assumed
to have 80% of its effects estimated from the meta-analyses. Under these assumptions, in a
population naïve to all polypill medications, polypill one is projected to potentially reduce
the incidence of CHD and stroke by 55% and 50%, respectively, and polypill two is
projected to potentially reduce the incidence of CHD and stroke by 50% and 51%,
respectively.
SUDAAN (version 9.1, Research Triangle Park, NC) was used for all NHANES analyses to
account for its complex sampling design. SAS (version 9.2, Cary, NC) was used for the
analysis of the pooled cohort data.
This research was, in part, funded through a grant from the National Institutes of Health.
The authors are solely responsible for the design and conduct of this study, all study
analyses, the drafting and editing of the paper and its final contents.
Results
Polypill-eligible population
Using the criteria of all US adults ≥ 55 years of age and those with a history of CVD, there
are 67.6 and 15.4 million US adults eligible for a polypill, respectively. Table 1 presents the
demographic characteristics and levels and prevalence of CVD risk factors for these two
populations.
Current medication use
Under current guidelines, 84.2% of US adults ≥ 55 years of age and all individuals with a
history of CVD are recommended aspirin (Table 2). Due to the presence of hypertension and
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high cholesterol, a majority of these two populations are recommended antihypertensive
medications and statins. However, among US adults ≥ 55 years of age who are
recommended each treatment, only 37.5%, 79.5%, and 58.6% were taking aspirin,
antihypertensive medications and statins, respectively. Among those with a history of CVD,
uptake rates of aspirin, antihypertensive medications and statins were 44.5%, 87.8%, and
64.6%, respectively. Additionally, among US adults with a history of myocardial infarction,
54.1% were taking beta-blockers.
CHD risk reduction
The 10 year incidence of CHD and stroke events in the pooled Framingham Offspring
Study, ARIC study, CHS cohorts were 10.7% and 6.7%, respectively, for adults ≥ 55 years
of age and 18.3% and 10.6%, respectively, for participants with a history of CVD (Figure 1,
top panels). After accounting for current medication use, it is projected that polypill use
among all US adults ≥ 55 years of age would potentially reduce the 10 year incidence of
CHD and stroke by 44% and 37%, respectively. The equivalent potential CHD and stroke
risk reductions for those with a history of CVD would be 32% and 30%, respectively. Over
10 years of follow-up, polypill use is projected to potentially result in 3.2 and 1.7 million
fewer CHD and stroke events, respectively, among US adults ≥ 55 years of age, and 0.9 and
0.5 million fewer CHD and stroke events, respectively, for US adults with a history of CVD
(Figure 1, bottom panels).
Side Effects
If polypills were taken by all US adults ≥ 55 years of age, adverse side effects are projected
to occur in 9.9% of users. The corresponding percentage for polypill use by US adults with a
history of CVD is 6.7%.
Sensitivity Analyses
Modeling the lower bound of risk benefits (i.e., the lower end of the expected risk reductions
from the meta-analyses), polypill use is projected to result in 18% and 23% reductions in
CHD and stroke, respectively, among US adults ≥ 55 years of age and 20% and 14% risk
reductions, respectively, for those with a history of CVD (Table 3). Modeling the upper
limits of benefits resulted in projected 58% and 48% reductions in CHD and stroke,
respectively, among US adults ≥ 55 years of age and 38% and 42% risk reductions,
respectively, for US adults with a history of CVD. Using the lower bound, side effects are
projected to occur in 5.0% and 2.8% of US adults ≥ 55 years of age and with a history of
CVD, respectively. Modeling the upper bounds, side effects are projected for 15.7% and
11.0% of these groups, respectively.
If only individuals currently taking an antihypertensive medication or a statin were to take a
polypill, the 10 year incidence of CHD and stroke would be reduced by 27% and 22%,
respectively, among US adults ≥ 55 years of age and by 25% and 24%, respectively, among
US adults with a history of CVD (Table 4). Use of polypills by individuals currently taking
at least one medication contained in the poylpill is projected to potentially prevent 2.4 and
1.1 million CHD and stroke events, respectively, among US adults ≥ 55 years of age and 1.4
and 0.7 million CHD and stroke events, respectively, among US adults with a history of
CVD.
In a final sensitivity analysis, the potential CHD and stroke prevention benefits were
calculated assuming each polypill medication had a sub-multiplicative effect of 80%
efficacy. Under this assumption, the use of polypills may potentially prevent 2.6 and 1.4
million CHD and stroke events, respectively, among US adults ≥ 55 years of age and 0.7
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and 0.4 million CHD and stroke events, respectively, among US adults with a history of
CVD.
Discussion
The current study suggests that cardiovascular risk reduction medications are under-utilized
among US adults. Even among the 15.4 million US adults with a history of CVD, fewer than
60% are taking aspirin and beta-blockers. We project that the population-wide use of
polypills containing aspirin, a thiazide-type diuretic, an ACE-inhibitor and a statin among all
US adults ≥ 55 years of age has the potential to prevent millions of CHD and stroke events
over the next 10 years. The potential for substantial risk reduction was also present when
polypills were considered only for US adults with a history of CVD.
Results from a recent randomized controlled trial indicated a polypill containing aspirin,
simvastatin, atenolol, ramipril and a thiazide diuretic improved individuals' cardiovascular
risk profile(24;25). In this trial, the polypill provided a similar degree of lowering blood
pressure and heart rate lowering effects when compared to its individuals antihypertensive
components. Additionally, the polypill resulted in a significant lowering of LDL-cholesterol
and urinary 11-dehydrothromboxane B2, compared to placebo. However, the effect in those
randomized to the polypill was less than their counterparts randomized to simvastatin (27
versus 32 mg/dL) and aspirin (283.1 versus 350.0 ng/mmol creatinine). Thus, the authors
concluded that the polypill being tested may not provide the benefits expected based on the
multiplicative effects of its individual components. Despite this caveat, based on the
reductions experienced for individuals randomized to receive this polypill (7.4 mmHg
reduction in systolic blood pressure, 27 mg/dL reduction in LDL-cholesterol and 283.1
reduction in ng/mmol creatinine 11-dehydrothromboxane B2), a substantial reduction in
CVD risk could be expected. In fact, in a sensitivity analysis assuming 20% lesser
reductions in events than expected from use of individual polypill medications, we project
that millions of CHD and stroke events may still be prevented over a 10 year period.
Prior epidemiological analyses have investigated the potential benefits of polypills. For
example, a study by Gaziano and colleagues reported a multi-drug primary prevention
strategy of treating patients from low and middle income countries with a 10-year absolute
risk of cardiovascular disease of more than 5% may result in reductions of 42% to 57% in
lifetime risk of death from cardiovascular disease(26). Additionally, a report “Assessing
Cost-Effectiveness in Prevention” from Australia detailed a potential for 230,000 disability-
adjusted life years gained through population-wide polypill use(27). The polypill was also
found to result in cost-savings.
While the projected potential benefits of polypills as estimated in the current study are
compelling, Lonn and colleagues recently described several reservations regarding the
polypill that need to be addressed prior to fully advocating their broad adoption (11).
Importantly, data are still needed from randomized controlled trials on the benefits of
polypills in preventing CHD and strokes. Additional items cited include determining the
ideal pharmaceutical formulation of polypills, polypill adherence issues, the abandonment of
healthy lifestyles by patients taking polypills, and the acceptability of taking additional
medications by the population at large. Caution is warranted until data become available to
address these uncertainties.
The expected benefits of wide-spread polypill use must be balanced by the projected
occurrence of new adverse side effects in up to 17% of its users. However, these will not
tend to be severe (e.g., cough, dizziness, nausea, and abdominal discomfort). While more
severe side effects (e.g., bleeding, angioedema) do occur with the use of the polypill drugs,
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these are unlikely to occur frequently. However, such side effects may also limit the
beneficial effects of polypill use.
Cardio-protective medications are under-utilized among US adults. The reasons why
patients do not take these medications are varied and include their beliefs about
pharmacologic medications, side effects, and lack of access to healthcare(28). Incorporating
aspirin, antihypertensive medications and statins into a single pill is widely predicted to
improve medication use and adherence(29). Several studies suggest that complex medication
taking regimens are an important barrier to achieving high medication adherence among
patients with hypertension and high cholesterol. The use of polypills has the potential to
make medication-taking regimens simpler, likely resulting in improved medication
adherence and possibly reduced CVD incidence.
The current study has potential limitations. For example, we relied on projections to estimate
the CHD and stroke risk reduction associated with polypill use. Additionally, while risk
reduction benefits and side effects are based on published data from randomized trials, 10
years of follow-up for the benefits and side effects were not available. Data are not currently
available on the risk reduction benefits of polypills and, thus, the potential benefits relied on
previously published meta-analyses. NHANES 2007-2008 provides nationally
representative estimates for the civilian non-institutionalized US population but it does not
have data on CHD and stroke incidence. Therefore, we used data from three large cohort
studies. Although these cohorts are population-based and maintain active follow-up and
adjudication of incident fatal and non-fatal CVD events, they are not based upon nationally
representative samples.
Several polypills aimed at CVD reduction are currently under development and being
evaluated in randomized controlled trials. While the CVD risk reduction benefits of polypills
still need to be determined in randomized controlled trials, the use of polypills among US
adults at high risk for CVD has the potential to prevent millions of CHD and stroke events.
Reference List
1. World Health Organization. WHO-Wellcome Trust meeting report 1-3. Geneva: 2002. Secondary
prevention of non-communicable disease in low and middle income countries through community-
based and health service interventions.
2. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;
326(7404):1419. [PubMed: 12829553]
3. Rodgers A. A cure for cardiovascular disease? Combination treatment has enormous potential,
especially in developing countries. BMJ. 2003; 326(7404):1407–1408. [PubMed: 12829526]
4. Watts G. What happened to the polypill? BMJ. 2008; 337:a1822. [PubMed: 18819953]
5. Fuster V, Sanz G. A polypill for secondary prevention: time to move from intellectual debate to
action. Nat Clin Pract Cardiovasc Med. 2007; 4(4):173. [PubMed: 17380163]
6. National Center for Health Statistics. NHANES Design and Conduct. 2008.
http://www.cdcgov/nchs/about/major/nhanes/
7. Perloff D, Grim CE, Flack JM, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure
determination by sphygmomanometry. Circulation. 1993; 88:2460–2470. [PubMed: 8222141]
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult
Treatment Panel III). JAMA. 2001; 285(19):2486–2497. [PubMed: 11368702]
9. Mosca L. Aspirin chemoprevention: one size does not fit all. Circulation. 2008; 117(22):2844–2846.
[PubMed: 18519859]
10. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines
for secondary prevention for patients with coronary and other atherosclerotic vascular disease:
Muntner et al. Page 7













2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;
113(19):2363–2372. [PubMed: 16702489]
11. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of
cardiovascular diseases: key concepts, current status, challenges, and future directions.
Circulation. 2010; 122(20):2078–2088. [PubMed: 21098469]
12. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health
outcomes associated with various antihypertensive therapies used as first-line agents: a network
meta-analysis. JAMA. 2003; 289(19):2534–2544. [PubMed: 12759325]
13. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and
secondary prevention of vascular disease: collaborative meta-analysis of individual participant
data from randomised trials. Lancet. 2009; 373(9678):1849–1860. [PubMed: 19482214]
14. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis
involving 121,000 patients. Am J Med. 2008; 121(1):24–33. [PubMed: 18187070]
15. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic
evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007; 11(14):
1–iv.
16. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for
use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J
Hypertens. 2006; 24(11):2131–2141. [PubMed: 17053529]
17. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for
hypertension. Cochrane Database Syst Rev. 2007; (1):CD002003. [PubMed: 17253471]
18. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other
blood- pressure-lowering drugs: results of prospectively designed overviews of randomised trials.
Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000; 356(9246):1955–1964.
[PubMed: 11130523]
19. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood
pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326(7404):1427.
[PubMed: 12829555]
20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein
cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;
326(7404):1423. [PubMed: 12829554]
21. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary
heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979; 110(3):281–
290. [PubMed: 474565]
22. The ARIC Study Investigators. The decline of ischaemic heart disease mortality in the ARIC study
communities. International Journal of Epidemiology. 1989; 18(3):S88–S98. [PubMed: 2681023]
23. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular
Health Study: design and rationale. Ann Epidemiol. 1991; 1(3):263–276. [PubMed: 1669507]
24. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on
risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-
blind, randomised trial. Lancet. 2009; 373(9672):1341–1351. [PubMed: 19339045]
25. Patel A, Shah T, Shah G, Jha V, Ghosh C, Desai J, et al. Preservation of bioavailability of
ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-
arm phase I crossover trial in healthy volunteers. Am J Cardiovasc Drugs. 2010; 10(2):95–103.
[PubMed: 20334446]
26. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug
regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006; 368(9536):679–686.
[PubMed: 16920473]
27. Vos, T.; Carter, R.; Barendregt, J.; Mihalopoulos, C.; Veerman, JL.; Magnus, A., et al. Assessing
Cost-Effectiveness in Prevention (ACE-Prevention): Final Report. University of Queensland,
Brisbane and Deakin University; Melbourne: 2010.
28. Ogedegbe G, Harrison M, Robbins L, Mancuso CA, Allegrante JP. Barriers and facilitators of
medication adherence in hypertensive African Americans: a qualitative study. Ethn Dis. 2004;
14(1):3–12. [PubMed: 15002917]
Muntner et al. Page 8













29. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical
applications. JAMA. 2002; 288(22):2880–2883. [PubMed: 12472330]
Muntner et al. Page 9














Percentage (top panel) and number (bottom panel) of US adults expected to have a coronary
heart disease event (left panels) or stroke (right panels) over the next 10 years with and
without us e of polypills.
History of cardiovascular disease (CVD) Includes individuals with a history of myocardial
infarction, coronary heart disease, or stroke
Without Polypill – Numbers are the product of the population size, estimated from
NHANES 1999-2004, times the 10-year coronary heart disease incidence rates estimated
using participants in the population-based Framingham Offspring Study, Atherosclerosis
Risk in Communities study (ARIC) and the Cardiovascular Health Study (CHS) meeting the
listed criteria.
With Polypill – Calculated as the observed coronary heart disease and stroke event rates in
the Framingham Offspring Study, ARIC and CHS multiplied by the event reductions
associated with the polypill medications as described in the methods section.
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Table 1
Characteristics of US adults ≥ 55 years of age and those with a history of cardiovascular disease.
US adults ≥ 55 years
(n=2554)
History of Cardiovascular Disease†
(n=592)
Mean (SD) age, years 66.9 (0.3) 65.1 (0.8)
Male sex, % 43.9% 54.7%
Race-ethnicity
 Non-Hispanic white, % 78.0% 75.8%
 Non-Hispanic black, % 9.6% 11.6%
 Mexican-American, % 7.7% 6.8%
Cigarette smoking, % 12.7% 21.7%
Mean (SD) systolic BP, mmHg 131.5 (0.7) 130.3 (1.1)
Mean (SD) diastolic BP, mmHg 68.9 (0.6) 68.1 (1.1)
Hypertension, % 60.1% 69.3%
Mean (SD) HDL-cholesterol, mg/dL 53.8 (0.6) 49.3 (0.6)
Mean (SD) LDL-cholesterol, mg/dL 116.5 (1.9) 102.9 (3.1)
High LDL-cholesterol, % 63.7% 88.3%
Diabetes mellitus, % 10.3% 15.6%
History of myocardial infarction, % 8.2% 46.0%
History of coronary heart disease, % 8.7% 45.5%
Angina, % 5.3% 20.9%
History of stroke, % 7.4% 44.1%
Abbreviations: SD – standard deviation; BP – blood pressure.
n represents number of participants in NHANES 2007-2008.
†
Includes a history of myocardial infarction, coronary heart disease, or stroke.
LDL-cholesterol is based on 977 participants ≥ 55 years and 240 participants with a history of cardiovascular disease and fasting samples.
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Table 4
Sensitivity analyses showing the percentage and number of US adults expected to have coronary heart disease
and stroke events over 10 years with and without the use of a polypill assuming only persons currently
antihypertensive medications or statins will take the polypill.
US adults ≥ 55 years History of CVD†
Number of US adults, millions 67.6 15.4
Number on antihypertensive or statin medication, millions 41.8 12.0
CHD Stroke CHD Stroke
10-year event rates
 Without polypill 10.7% 6.7% 18.3% 10.6%
 With polypill 7.8% 5.2% 13.8% 8.1%
 % reduction 27% 22% 25% 24%
Events, millions
 Without polypill 7.2 4.5 2.8 1.6
 With polypill 5.3 3.5 2.1 1.2
 Prevented events 1.9 1.0 0.7 0.4
CVD – cardiovascular disease, CHD – coronary heart disease
†
Includes individuals with a history of myocardial infarction, coronary heart disease, or stroke
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